The role of glucose metabolism and glycolysis in RCC CD8+ TIL activation was tested using 2-deoxy-d-glucose (2-DG), a competitive inhibitor that reduces glucose-6-phosphate production from glucose. Here, CD8A is linked to renal cell carcinoma.